NasdaqGS:MRVILife Sciences
Maravai LifeSciences Q1 Turnaround Spurs Rethink Of CleanCap Driven Outlook
Maravai LifeSciences Holdings (NasdaqGS:MRVI) reported a 41% jump in Q1 2026 revenue.
The company sharply narrowed its net loss and posted positive Adjusted EBITDA in the quarter.
Results were supported by a large CleanCap vaccine order and meaningful debt reduction.
For investors following NasdaqGS:MRVI, this Q1 2026 update marks a clear break from recent coverage that focused on ongoing losses and softer growth. The stock is trading at $4.37, with the share price up 10.9% over the past...